| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 9, 2022 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | Outperform | William Blair | |
| 1/18/2022 | $2.00 | Buy | HC Wainwright & Co. |
NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New Geographic Markets Will Severely Impair its Earnings Potential Identifies at Least Ten Other Areas of Misperception That Suggest Floor & Decor's Challenges Are Structural and Are Not Cyclical or Easily Fixed Provides Evidence That Floor & Decor Recently Made Revisions to Key Revenue Claims, Numerous Omissions of Past Disclosures, Changes to Accounting Policy Language and Modifications to Business Practices That Obscure its Growing Challenges Provides Evidence That CEO Thom
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it has initiated the multiple ascending dose ("MAD") portion of the ongoing Phase 1 clinical trial
New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX's novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company"). The new name, logo, website, and brand
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second qua
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights. To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conferenc
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales Sale reflects Brickell's new business strategy and commitment to developing its pipeline of novel, potential first-in-class treatments in immunology and inflammation On track to initiate a Phase 1 study of BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases, in the second quarter of 2022, with SAD and MAD topline results expected by early 2023 BOULDER, Colo., May 12, 2022 (GLOBE
10-Q - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)
SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)
SC 13G - Brickell Biotech, Inc. (0000819050) (Subject)
William Blair initiated coverage of Brickell Biotech with a rating of Outperform
HC Wainwright & Co. initiated coverage of Brickell Biotech with a rating of Buy and set a new price target of $2.00
4 - Brickell Biotech, Inc. (0000819050) (Issuer)
4 - Brickell Biotech, Inc. (0000819050) (Issuer)
4 - Brickell Biotech, Inc. (0000819050) (Issuer)
BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it has appointed Monica Luchi, MD, FACR, MBA to the newly created role of Chief Medical Officer. In this new role, Dr. Luchi will oversee the Company's clinical development strategy and medical affairs functions. "We are delighted to have Dr. Luchi join our team at this transformative point in our Company's history. Her tremendou